Tectonic Therapeutic (NasdaqGM:TECX) Update / briefing February 24, 2026 11:00 AM ET Company ParticipantsAlex Nackenoff - Biotechnology Equity Research AssociateAlise Reicin - President and CEODavid Risinger - Senior Managing DirectorGaurav Maini - VP of Biotech Equity ResearchHanny Al-Samkari - Associate Professor of MedicineMarcie Ruddy - Chief Medical OfficerMartin Auster - Managing DirectorPeter McNamara - Chief Scientific OfficerConference Call ParticipantsBen Burnett - AnalystLeland Gershell - Managin ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northen District of California on behalf of all persons or entities who purchased or otherwise acquired Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) securities between October 31, 2024, and December 30, 2025, inclusive (the “Class Period”). The Complaint alleges that Defendants represented that the k ...

Larimar Therapeutics, Inc. (LRMR) shares soared 34.34 percent to $3.77, up $0.96 on Tuesday, after the company announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to nomlabofusp for the treatment of Friedreich's ataxia. The stock is currently trading at $3.9200, compared with a previous close of $2.8100. It opened at $3.5900 and has traded between $3.5500 and $4.0000 during the session. Trading volume has surged to 43.95 million shares, far exceeding its average vo ...

We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on RARE. Ultragenyx Pharmaceutical Inc.'s share was trading at $23.88 as of February 9th. Zoetis (ZTS) Hits New 52-Week Low on Dismal Outlook M. A. Arkhipov/Shutterstock.com Ultragenyx Pharmaceuticals positions itself as a diversified rare disease company with four approved products generating approximately $670 million in annual ...

Palvella Therapeutics stock is trading near recent highs. Where are PVLA shares going?Phase 3 SELVA Trial SucceedsThe trial in 49 patients aged six and older met its primary endpoint on the Microcystic Lymphatic Malformation Investigator Global Assessment, with a mean improvement of over two points and gains across all key secondary measures. Most participants were rated much or very improved, and nearly all eligible patients chose to roll into an extension study.First Potential Therapy For MicrocysticQTORI ...

Key Takeaways Iovance's Amtagvi sales jumped 183% in the first nine months of 2025, driving growth.IOVA cut its 2025 revenue guidance and withdrew its EU filing for Amtagvi, hurting shares.Rigel's 2025 sales rose 60% to $232M, led by Tavalisse, with 2026 growth projected.Both Iovance Biotherapeutics (IOVA) and Rigel Pharmaceuticals (RIGL) are small-cap companies focused on the successful commercialization of their marketed products.While Iovance is a cancer biotech concentrated on developing immunotherapies ...

Harmony Biosciences (NasdaqGM:HRMY) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsAdam Zaeske - EVP and Chief Commercial OfficerJeffrey M. Dayno - President and CEOKumar Budur - Chief Medical and Scientific OfficerMatthew Beck - Investor RelationsPatrick Trucchio - Managing Director of Equity ResearchPoorna Kannan - Biotech Equity Research AssociateSandip Kapadia - CFO and Chief Administrative OfficerConference Call ParticipantsBhavin Patel - AnalystCorinne Johnson - AnalystDavid A ...

Apellis Pharmaceuticals (NasdaqGS:APLS) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsAnupam Rama - Biotechnology Equity ResearchCaroline Baumal - CMOCedric Francois - Co-Founder, CEO, and PresidentDavid Acheson - EVP of CommercialDouglas Tsao - Managing Director of Equity ResearchEllie Merrill - Biotechnology Equity Research AssociateEva Stroynowski - Investor Relations and Corporate Affairs Biotechnology ExecutiveJayad Momin - Biopharma Equity Research AssociateJonathan Miller - ...

Harmony Biosciences (NasdaqGM:HRMY) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsAdam Zaeske - EVP and Chief Commercial OfficerJeffrey M. Dayno - President and CEOKumar Budur - Chief Medical and Scientific OfficerMatthew Beck - Investor RelationsPatrick Trucchio - Managing Director of Equity ResearchPoorna Kannan - Biotech Equity Research AssociateSandip Kapadia - CFO and Chief Administrative OfficerConference Call ParticipantsBhavin Patel - AnalystCorinne Johnson - AnalystDavid A ...

Iovance Biotherapeutics (NasdaqGM:IOVA) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsAndrew Tsai - Managing DirectorBrian Gastman - EVP of Transitional Medicine and ResearchCorleen Roche - CFODan Kirby - Chief Commercial OfficerDavid Dai - DirectorFrederick Vogt - Interim CEO and PresidentIgor Bilinsky - COOReni Benjamin - Managing DirectorSara Pellegrino - SVP of Investor Relations and Corporate CommunicationsNone - Company RepresentativeConference Call ParticipantsAsthika Goonew ...